Tissue Regenix (LON:TRX) has strengthened the management of its US operation with the appointment of Drew Distin to its new orthopaedic subsidiary.
Distin is a specialist in building sales through targeted marketing and has worked for a number of other US companies.
His remit is to plan the launch Tissue Regenix’s new range of orthopaedic products on the US.
Clinical trials are currently ongoing in Europe for OrthoPure XM (porcine meniscus) and OrthoPure XT (porcine tendon) products, with the a target a CE mark for the XM knee cartilage by the end of 2016.
In the US, Tissue will initially focus on human tissue applications, initially starting with the human tendon (OrthoPure HT).
Tissue Regenix is currently in partnership with tissue bank Community Tissue Services (CTS) for the manufacturing of its wound care product DermaPure.
Peter Hamer, Tissue Regenix Orthopaedic’s commercial director, said Distin brings a wealth of experience.
“This is a very exciting time for Orthopaedics at Tissue Regenix as we continue enrolment of our OrthoPure XT clinical trial and await submission for the CE mark with OrthoPure XM.
“We are on course to complete these tasks within the timeline predicted."